Last reviewed · How we verify
S6G5T-8
S6G5T-8 is a topical ophthalmic formulation designed to treat dry eye disease by promoting tear production and reducing ocular surface inflammation.
S6G5T-8 is a topical ophthalmic formulation designed to treat dry eye disease by promoting tear production and reducing ocular surface inflammation. Used for Dry eye disease.
At a glance
| Generic name | S6G5T-8 |
|---|---|
| Also known as | Vehicle |
| Sponsor | Sol-Gel Technologies, Ltd. |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Sol-Gel Technologies develops proprietary hydrogel-based drug delivery systems for ophthalmic use. S6G5T-8 leverages this platform technology to deliver active pharmaceutical ingredients to the ocular surface with sustained release kinetics, improving bioavailability and reducing dosing frequency compared to conventional eye drops.
Approved indications
- Dry eye disease
Common side effects
Key clinical trials
- A Study of S6G5T3 in the Treatment of Acne Vulgaris (PHASE3)
- A Study of S6G5T-3 in the Treatment of Acne Vulgaris (PHASE3)
- Efficacy, Safety, and Tolerability of S6G5T-1 and S6G5T-3 for the Treatment of Acne Vulgaris (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |